TOP TIERMARKET NEWSWIRE
News & sentiment

CLIMB BIO INC (CLYM) — News & AI sentiment

CLIMB BIO INC (CLYM) news roundup. 12 stories in the past week, 20 over 30 days. Average 30-day sentiment is 60.7/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $1.4M — net selling of $1.4M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
12
avg sentiment 60.6/100
30d stories
20
avg sentiment 60.7/100
Insider net (90d)
$1.4M
0 buys · 1 sells
Congress (90d)
0
0 buys · 0 sells

CLYM news in the last 24 hours, 7 days, 30 days and 90 days

How much CLYM coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowCLYM storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days1260.6/100CLYM headlines →
Last 30 days2060.7/100CLYM headlines →
Last 90 days5259.3/100CLYM headlines →

Latest stories on CLYM

Piper Sandler reiterates Climb Bio stock rating after ASN data
Investing.com Analyst Ratings52 · neutralanalyst
1d ago
Climb Bio management to meet with Truist
The Fly56 · neutralgeneral
2d ago
3d ago
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
3d ago
Climb Bio announces new data for budoprutug
The Fly58 · neutralproduct/pr
3d ago
4d ago
4d ago
5d ago
Climb Bio, Inc. (CLYM) files 8-K
SEC 8-K50 · neutralgeneral
5d ago
5d ago
5d ago
5d ago
Oct 20
Why is Climb Bio stock surging today?
Investing.com Markets64 · neutralgeneral
Oct 20
Climb Bio stock initiated at buy by Deutsche Bank on autoimmune pipeline
Investing.com Analyst Ratings63 · neutralanalyst
Oct 20
Oct 20
H.C. Wainwright reiterates Climb Bio stock rating ahead of data
Investing.com Analyst Ratings52 · neutralanalyst
Oct 12
Oct 7
Oct 2
Oct 2
Sep 23
Raymond James adds Climb Bio stock to favorites list on drug potential
Investing.com Analyst Ratings63 · neutralanalyst
Sep 23
Sep 23
Sep 17
Sep 8
Open CLYM in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →